All Clinical Trials

A listing of 23094 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Heat Therapy in Older Hypertensive Women

NCT03857490

Recruiting

The prevalence of hypertension is greater in older women than men, while the blood pressure (BP) control rate is lower in older women in US. Uncontrolled hypertension is a major risk factor for cardiovascular morbidity/mortality. Despite standard therapy and adherence to optimal drug regimens, \>50% of older hypertensive women still have inadequate BP control, and the control rate is further reduced with more aggressive BP targets recommended recently by the new Hypertension Guidelines. Thus, the effectiveness of drug treatment alone in the control of hypertension among older women is limited; hence, non-pharmacological approaches are also needed to help reduce BP in older hypertensive women. One adjuvant, non-pharmacological approach that offers promise in lowering BP is "heat therapy". Indeed, repeated whole-body heat exposure decreases BP in healthy humans. Whether this is also true after regional limb heating in hypertensive patients is unknown. The objectives of this research are to investigate the BP lowering effect of home-based lower leg heat therapy in older women with hypertension, and to examine the impact of this therapeutic modality on neural-vascular health in these patients. Aim 1 will test the hypothesis that chronic lower leg heat therapy combined with an antihypertensive drug is superior to drug treatment alone in lowering BP in older hypertensive women. We will randomly assign older hypertensive women to either an intervention group or a control group. Patients in the intervention group will perform 8 weeks of lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times/week, 45 min/session), whereas patients in the control group will immerse their legs in a thermoneutral water bath (33°C) at the same frequency and duration. All patients will also receive a fixed dose of chlorthalidone (a diuretic, 25 mg orally daily). We will compare ambulatory BP, the BP control rate, and patient adherence and acceptability to treatment between the groups. Aim 2 will test the hypothesis that chronic lower leg heat therapy will improve nitric oxide bioavailability which can decrease sympathetic vasoconstriction and improve vascular function in older hypertensive women. We will use state-of-the-art techniques of microneurography, Doppler ultrasound, applanation tonometry, and cutaneous microdialysis to assess neural control, vasodilator function, and interstitial metabolites (i.e. nitrate and nitrite) indicative of basal nitric oxide bioavailability in all patients enrolled in Aim 1 before and after 8 weeks of heat therapy. Information obtained from this research project will guide evidence-based clinical practice. It is anticipated that our study may lead to revision of hypertension guidelines to incorporate home-based heat therapy as adjuvant to antihypertensive drug(s) for older women, as well as other patient populations. Read Less

Gender:

FEMALE

Ages:

Between 65 years and 85 years

Trial Updated:

05/23/2025

Locations: Institute for Exercise and Environmental Medicine, Dallas, Texas

Conditions: Essential Hypertension

Learn More ›

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Recruiting

The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of c... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California +22 locations

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

Los Angeles General Medical Center, Los Angeles, California

USC / Norris Comprehensive Cancer Center, Los Angeles, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Memorial Hospital East, Shiloh, Illinois

National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland

National Institutes of Health Clinical Center, Bethesda, Maryland

Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Siteman Cancer Center-South County, Saint Louis, Missouri

Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri

Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri

NYP/Weill Cornell Medical Center, New York, New York

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

University of Texas at Austin, Austin, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

University of Texas Medical Branch, Galveston, Texas

M D Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

Conditions: Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Advanced Colon Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Salivary Gland Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Salivary Gland Carcinoma, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Salivary Gland Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Learn More ›

Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism

NCT05047354

Recruiting

Background: Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder. It can cause birth defects and developmental delays. There is no cure for SLOS or other inherited diseases related to cholesterol production or storage. The data gained in this study may help researchers find ways to measure how well future treatments work. Objective: To learn more about SLOS and related disorders and how these diseases affect participants and relatives. Eligibility: People of any age who have or are suspe... Read More

Gender:

ALL

Ages:

Between 1 day and 100 years

Trial Updated:

05/23/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Smith Lemli Opitz Syndrome, CHILD Syndrome, Lathosterolosis, Desmosterolosis

Learn More ›

Simplified Post Op Rehabilitation for Ankle and Pilon Fractures

NCT05280639

Recruiting

The aim of this study is to compare standard post operative rehabilitation with a simplified wooden block stretching protocol that will yield similar results.

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

05/23/2025

Locations: University of Virginia Medical Center, Charlottesville, Virginia

Conditions: Ankle Fractures, Pilon Fracture

Learn More ›

Oral N-acetylcysteine for Retinitis Pigmentosa

NCT05537220

Recruiting

Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

05/23/2025

Locations: University of California - Davis, Department of Ophthalmology & Vision Science, Davis, California +30 locations

University of California - Davis, Department of Ophthalmology & Vision Science, Davis, California

University of Southern California, Keck School of Medicine, Los Angeles, California

University of California - San Francisco, Department of Ophthalmology, San Francisco, California

Stanford University, Byers Eye Institute, Stanford, California

Vitreo Retinal Associates, Gainesville, Florida

University of Florida - Jacksonville, UF Health Jacksonville, Jacksonville, Florida

University of Miami, Bascom Palmer Eye Institute, Miami, Florida

Emory University, Emory Eye Center, Atlanta, Georgia

University Of Illinois At Chicago, Chicago, Illinois

Northwestern University, Evanston, Illinois

University of Iowa, Carver College of Medicine, Iowa City, Iowa

Wilmer Eye Institute- Johns Hopkins University, Baltimore, Maryland

Harvard University, Mass. Eye and Ear, Boston, Massachusetts

University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan

University of Minnesota, Department of Ophthalmology and Visual Neurosciences, Minneapolis, Minnesota

Mayo Clinic, Department of Ophthalmology, Rochester, Minnesota

University of Oklahoma, Dean McGee Eye Institute, Oklahoma City, Oklahoma

Scheie Eye Institute, Philadelphia, Pennsylvania

Vanderbilt University, Vanderbilt Eye Institute, Nashville, Tennessee

Retina Foundation of the Southwest, Dallas, Texas

University of Utah, Moran Eye Center, Salt Lake City, Utah

University of Washington, Department of Ophthalmology, Seattle, Washington

University of Wisconsin - Madison, McPherson Eye Research Institute, Madison, Wisconsin

Medical College of Wisconsin, The Eye Institute, Milwaukee, Wisconsin

Medical University of Graz, Department of Ophthalmology, Graz, Styria

McGill University, The Research Institute of the McGill University Health Center, Montréal, Quebec

University of Tübingen, Department für Augenheilkunde, Tübingen, Baden-Württemberg

Radboud University, Radboud University Medical Centre, Nijmegen, Gelderland

University of Amsterdam, Amsterdam Medical Center, Amsterdam, Northern Holland

Universitätsspital Basel, Eye Clinic, Basel, Not set

University College London, Moorfields Eye Hospital, London, England

Conditions: Retinitis Pigmentosa

Learn More ›

A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

NCT05734105

Recruiting

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or di... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: UC San Diego Moores Cancer Center, La Jolla, California +63 locations

UC San Diego Moores Cancer Center, La Jolla, California

Yale University, New Haven, Connecticut

Mayo Clinic Florida, Jacksonville, Florida

Sylvester Comprehensive Cancer Center, Miami, Florida

Moffitt Cancer Center, Tampa, Florida

Johns Hopkins Hospital, Baltimore, Maryland

Boston Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Memorial Sloan Kettering Cancer Center, New York, New York

Northwell Health Cancer Institute/ R.J. Zuckerberg Cancer Center, New York, New York

Cleveland Clinic, Cleveland, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

Oregon Health & Science University, Portland, Oregon

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

The University of Texas MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson Cancer Center, Seattle, Washington

Prince of Wales Hospital, Randwick, New South Wales

Alfred Health, Melbourne, Victoria

CEPEN - Centro de Pesquisa e Ensino em Saude de Santa Catarina, Florianópolis, Santa Catarina

Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Sao Paulo

Hospital Sirio-Libanes, São Paulo, Sao Paulo

Hospital 9 de Julho, São Paulo, SP

INCA - Instituto Nacional de Cancer, Rio De Janeiro, Not set

AC Camargo Câncer Center, São Paulo, Not set

Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta

Juravinski Cancer Centre, Hamilton, Ontario

University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario

McGill University Health Centre, Montréal, Quebec

Clínica San Carlos De Apoquindo Red Salud UC Christus, Las Condes, RM

Centro de Oncología de Precisión, Santiago, RM

CHU Dijon, Dijon Cedex, Bourgogone

Centre Eugène Marquis, Rennes, Ille Et Vilaine

Institut Bergonié, Bordeaux, Not set

Centre Léon Bérard, Lyon, Not set

Institut Gustave Roussy, Villejuif, Not set

Helios Klinikum Berlin-Buch, Berlin, Not set

University Hospital Essen (Universitätsklinikum Essen), Essen, Not set

Istituto Nazionale Tumori IRCCS Fondazione "G Pascale", Naples, Napoli

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

Istituto Oncologico Veneto-IOV IRCCS, Padova, Not set

U.O.C. Oncologia Medica, Palermo, Not set

Università Campus Bio-Medico di Roma, Roma, Not set

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

UMC Groningen, Groningen, Not set

LUMC, Leiden, Not set

Oslo University Hospital, Oslo, Not set

Narodowy Instytut Onkologii Im . Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warsaw, Warszawa

Complejo Hospitalario Universitario de Vigo - Hospital Alvaro Cunqueiro, Vigo, Pontevedra

Hospital Universitario Vall d'Hebron, Barcelona, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital General Universitario Gregorio Marañon, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Instituto Valenciano de Oncologia - IVO, Valencia, Not set

China Medical University Hospital, Taichung, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

The Royal Marsden Hospital NHS Foundation Trust, London, Greater London

St. James University Hospital, Leeds, West Yorkshire

Conditions: GIST

Learn More ›

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

NCT05818683

Recruiting

The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).

Gender:

MALE

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Florida Cancer Specialists, Sarasota, Florida +10 locations

Conditions: Metastatic Castration-resistant Prostate Neoplasms

Learn More ›

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

NCT05987449

Recruiting

WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors. The overall aim of the study is to investigate the safety, tolerability, pharmaco... Read More

Gender:

MALE

Ages:

Between 2 years and 59 years

Trial Updated:

05/23/2025

Locations: UC Davis Cancer Center, Sacramento, California +11 locations

Conditions: Hemophilia A

Learn More ›

Investigation of a 3 oz Water Protocol on Patients With Tracheostomies

NCT06120790

Recruiting

Examining the validity of a novel 3 oz protocol in patients with tracheostomies as compared to the gold standard of instrumental swallow assessments (Flexible Endoscopic Evaluation of the Swallow or Modified Barium Swallow Study).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Mount Sinai Hospital, New York, New York

Conditions: Tracheostomy

Learn More ›

Virtual Incentive Treatment for Alcohol

NCT06265506

Recruiting

The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) o... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: Washington State University, Spokane, Washington

Conditions: Alcohol Use Disorder, Alcohol Drinking, Alcohol Abuse, Alcohol Dependence

Learn More ›

A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995

Recruiting

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/23/2025

Locations: AllerVie Clinical Research, Birmingham, Alabama +157 locations

AllerVie Clinical Research, Birmingham, Alabama

University of Alabama at Birmingham, Birmingham, Alabama

Keck Medicine of USC, Arcadia, California

University of California, Irvine, Irvine, California

DaVinci Research LLC, Roseville, California

Breathe Clear Institute, Torrance, California

Colorado ENT & Allergy, Colorado Springs, Colorado

Orlando ENT & Allergy, Orlando, Florida

NuLine Clinical Trial Center, Pompano Beach, Florida

University of South Florida, Tampa, Florida

Treasure Valley Medical Research, Boise, Idaho

Chicago ENT, Chicago, Illinois

South Louisiana Ear, Nose, Throat & Facial Plastic Surgery - PPDS, Mandeville, Louisiana

Chesapeake Clinical Research, Inc., White Marsh, Maryland

Brigham and Women's Hospital, Boston, Massachusetts

University of Missouri, Columbia, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Madison ENT & Facial Plastic Surgery, New York, New York

UCMC, Cincinnati, Ohio

Optimed Research, LTD, Columbus, Ohio

Specialty Physician Associates, Bethlehem, Pennsylvania

Medical University of South Carolina- Department of Otolaryngology and Head and Neck Surgery, Charleston, South Carolina

UT Southwestern Medical Center, Dallas, Texas

University of Texas Physicians Department of Otorhinolaryngology Clinc, Houston, Texas

Ear Nose and Throat Associates of Texas PA, McKinney, Texas

Alamo ENT Associates, San Antonio, Texas

Eastern Virginia Medical School, Norfolk, Virginia

Richmond Ear Nose and Throat, Richmond, Virginia

The Medical College of Wisconsin, Milwaukee, Wisconsin

UZ Gent, Gent, Oost-Vlaanderen

Pneumocare, Erpent, Not set

Cliniques Universitaires Saint-Luc Avenue Hippocrate 10, Sint-Lambrechts-Woluwe, Not set

Multiprofile Hospital For Active Treatment Dr Tota Venkova A, Gabrovo, Not set

Medical Center Medconsult Pleven OOD, Pleven, Not set

Diagnostic-Consultative Centre Ascendent EOOD, Sofia, Not set

Military Medical Academy - Multiprofile Hospital for Active Treatment - Sofia,, Sofia, Not set

University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna, Sofia, Not set

Multiprofile Hospital for Active treatment Trakia EOOD, Zagora, Not set

St. Joseph's Hospital, Ontario, Not set

CSAC, Québec, Not set

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui

Peking University Third Hospital, Beijing, Beijing

Beijing Hospital, Beijing, Beijing

The First Affiliated Hospital Of Fujian Medical University, FuZhou, Fujian

The People's Hospital of Guangxi Zhuang Autonomous Region, Nan Ning, Guang XI

Hainan General Hospital, Haikou, Hainan

Renmin Hospital of Wuhan University, Wu Han, Hubei

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Huai'an First People's Hospital, Huai'an, Jiangsu

The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Shengjing Hospital of China Medical University, Shenyang, Liaoning

First People's Hospital of Yinchuan, Yinchuan Shi, Ningxia

The First Hospital of Shanxi Medical University, Taiyuan, Shanxi

Sichuan Provincial People's Hospital, Chengdu, Sichuan

Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang

Beijing Tongren Hospital, Beijing, Not set

The Third Xiangya Hospital of Central South University, Changsha City, Not set

The First People's Hospital of Foshan, Foshan, Not set

Shenzhen Second People's Hospital, Guangdong, Not set

Hangzhou First People's Hospital, Hangzhou City, Not set

The first Affilliated Hospital Shandong First Medical University, Shandong, Not set

Tongji Hospital of Tongji University, Shanghai, Not set

Tianjin People's Hospital, Tianjin, Not set

Tonghua Central Hospital, Tonghua City, Not set

The 2nd Affiliated Hospital of Wenzhou Medical University, Wenzhou Avenue, Not set

Aalborg Universitetshospital Medicinerhuset Lungemedicinsk Forskningsenhed, Aalborg, Not set

Aarhus University Hospital, Dept. of Ear-Nose-Throat, Aarhus, Not set

Bispebjerg Hospital Department of Respiratory Medicine, Copenhagen, Not set

Sjællands Universitets Hospital, Køge, Not set

Universitätsklinikum Schleswig-Holstein, Lübeck, Schleswig-Holstein

Charite-Universitatsmedizin Berlin, Berlin, Not set

HNO Zentrum am Kudamm, Berlin, Not set

Praxis für HNO und Allergologie, Dresden, Not set

Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Not set

IKF Pneumologie, Frankfurt am Main, Not set

Universitätsklinikum Jena, Jena, Not set

HNO Praxis, Sachsen, Not set

Ospedale San Raffaele, Milano, Lombardia

AOU Careggi- University of Florence, Florence, Not set

AOU Federico II Via Pansini, Napoli, Not set

Azienda Ospedaliera Di Padova, Padova, Not set

Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara, Pisa, Not set

Fondazione Policlinico A. Gemelli IRCCS, Rome, Not set

ASST Brianza - Vimercate Hospital, Vimercate, Not set

Kimitsu Chuo Hospital, Kisarazu, Chiba

1-8-1, Kishinoura, Kitakyushu, Fukuoka

Mie University Hospital, Tsu, Mie

Osaka Habikino Medical Center, Habikino-shi, Osaka

Kansai Medical University Hospital, Hirakata, Osaka

Kansai Electric Power Hospital, Osaka-shi, Osaka

Kyosai Hospital, Minami-Alps, Yamanashi

University of Yamanashi Hospital, Chuo, Yamanshi

Toyota Memorial Hospital, Aichi, Not set

Clinic Kashiwanoha, Chiba, Not set

University of Fukui Hospital, Fukui, Not set

Saiseikai Fukuoka General Hospital, Fukuoak, Not set

Matsuda Hospital, Fukuoka, Not set

Kyushu University Hospital, Fukuoka, Not set

Hyogo Medical University Hospital, Hyogo, Not set

Takarazuka City Hospital, Hyogo, Not set

Ibaraki Prefectural Central Hospital, Ibaraki, Not set

Kagoshima Kouseiren Hospital, Kagoshima, Not set

Yokohama City Minato Red Cross Hospital, Kanagawa, Not set

Odawara Municipal Hospital, Kanagawa, Not set

3-54-2, Kotohirahommachi, Kumamoto, Not set

Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Not set

Ritsuzankai Iida Hospital, Nagano, Not set

Asahioka, 1-24, Niigata, Not set

Niigata University Medical & Dental Hospital, Niigata, Not set

Japan Community Health care Organization Osaka Hospital, Osaka, Not set

8-2 Otemachi, Shizuoka, Not set

Toho University Ohashi Medical Center, Tokyo, Not set

Nihon University Itabashi Hospital, Tokyo, Not set

JCHO Shimonoseki Medical center, Yamaguchi, Not set

Seoul National University Bundang Hospital, Seongnam-si, Geonggi-do

Ajou University Hospital, Suwon, Gyeonggi-do

Pusan National University Hospital, Pusan, Korea

Korea University Anam Hospital, Seoul, Seoul-teukbyeolsi [Seoul]

Inje University Haeundae Paik Hospital, Busan, Not set

CHA Bundang Medical Center, Gyeonggi-do, Not set

SNUH - Seoul National University Hospital, Seoul, Not set

The Catholic University of Korea, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

SMG-SNU Boramae Medical Center, Seoul, Not set

Niepubliczny Zakład Opieki Zdrowotnej E-Vita, Białystok, Not set

Centrum Medyczne Angelius Provita, Katowice, Not set

B&R Clinical Sp. z o.o, Kielce, Not set

Centrum Medyczne All-Med, Krakow, Not set

Centrum Medyczne Promed ul. Olszańska 5G, Krakow, Not set

Specjalistyczny Niepubliczny Zakład Opieki Zdrowotnej Alergologia Plus Ośrodek Diagnostyki, Poznań, Not set

Centrum Medyczne Biotamed Morawska Barbara, Wieliczka, Not set

EMC INSTYTUT MEDYCZNY S.A. Przychodnia, Wroclaw, Not set

Centrum Medyczne Oporów, Wroclaw, Not set

Centrum Medyczne Pratia Katowice, Katowice, Śląskie

Centrul Medical Unirea SRL, Brasov, Not set

Centrul Medical De Diagnostic Si Tratament Ambulator Neomed S.R.L, Brasov, Not set

Euroclinic Hospital SA, Bucharest, Not set

Delta Health Care S.R.L, Bucuresti, Not set

Cardiomed S.R.L, Cluj-Napoca, Not set

Centrul de Excelenta in Rinologie S.R.L, Dolj, Not set

Hospital Universitario Virgen de la Macarena Avenida Dr. Fedriani, Andalucia, Not set

Centro Médico Teknon, Barcelona, Not set

Hospital Universitario de Jerez, Cadiz, Not set

Hospital Clínico Universitario de Santiago, Galícia, Not set

FutureMeds DKF, Madrid, Not set

Hospital Universitario Fundación Jiménez Díaz, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Taipei Medical University Shuang Ho Hospital, New Taipei, Not set

National Taiwan University Hospital, Taipei, Not set

Stepping Hill Hospital, Stockport, Cheshire

Charing Cross Hospital, Chelsea, London

Bristol Royal Infirmary University Hospitals, Bristol, Not set

James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, Not set

Royal Berkshire NHS Foundation Trust, London, Not set

Guys and St Thomas' NHS Foundation Trust, London, Not set

Newcastle upon Tyne Hospitals NHSFT Freeman Hospital, Newcastle upon Tyne, Not set

Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Learn More ›

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449

Recruiting

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) \[polymyositis (PM) or dermatomyositis (DM)\] while receiving standard of care (SoC) treatment.

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

05/23/2025

Locations: Research Site, Irvine, California +201 locations

Research Site, Irvine, California

Research Site, Aurora, Colorado

Research Site, Denver, Colorado

Research Site, New Haven, Connecticut

Research Site, Washington, District of Columbia

Research Site, Boca Raton, Florida

Research Site, Boynton Beach, Florida

Research Site, Gainesville, Florida

Research Site, Margate, Florida

Research Site, Miami, Florida

Research Site, Orlando, Florida

Research Site, Atlanta, Georgia

Research Site, Fairway, Kansas

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Ann Arbor, Michigan

Research Site, Durham, North Carolina

Research Site, Cleveland, Ohio

Research Site, Middleburg Heights, Ohio

Research Site, Pittsburgh, Pennsylvania

Research Site, Allen, Texas

Research Site, Colleyville, Texas

Research Site, North Richland Hills, Texas

Research Site, Milwaukee, Wisconsin

Research Site, Buenos Aires, Not set

Research Site, Quilmes, Not set

Research Site, San Miguel de Tucuman, Not set

Research Site, Camperdown, Not set

Research Site, Nedlands, Not set

Research Site, New Lambton, Not set

Research Site, Southport, Not set

Research Site, Woodville South, Not set

Research Site, Graz, Not set

Research Site, Gent, Not set

Research Site, Leuven, Not set

Research Site, Merksem, Not set

Research Site, Joinville, Not set

Research Site, Juiz de Fora, Not set

Research Site, Pelotas, Not set

Research Site, Porto Alegre, Not set

Research Site, Salvador, Not set

Research Site, Sao Jose Do Rio Preto, Not set

Research Site, Sao Paulo, Not set

Research Site, Haskovo, Not set

Research Site, Plovdiv, Not set

Research Site, Sofia, Not set

Research Site, Stara Zagora, Not set

Research Site, Calgary, Alberta

Research Site, Montreal, Quebec

Research Site, Concepcion, Not set

Research Site, Osorno, Not set

Research Site, Santiago, Not set

Research Site, Beijing, Not set

Research Site, Chongqing, Not set

Research Site, Dongguan, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Hengyang, Not set

Research Site, Jining, Not set

Research Site, Nanjing, Not set

Research Site, Shanghai, Not set

Research Site, Wenzhou, Not set

Research Site, Zhengzhou, Not set

Research Site, Praha 2, Not set

Research Site, Aarhus N, Not set

Research Site, Copenhagen, Not set

Research Site, Odense C, Not set

Research Site, Angers, Not set

Research Site, Brest Cedex 2, Not set

Research Site, Le Mans Cedex, Not set

Research Site, Lille Cedex, Not set

Research Site, Lyon, Not set

Research Site, Paris Cedex 13, Not set

Research Site, Paris, Not set

Research Site, Reims, Not set

Research Site, Rouen, Not set

Research Site, Strasbourg, Not set

Research Site, Toulouse, Not set

Research Site, Bad Nauheim, Not set

Research Site, Berlin, Not set

Research Site, Bonn, Not set

Research Site, Freiburg, Not set

Research Site, Herne, Not set

Research Site, München, Not set

Research Site, Tübingen, Not set

Research Site, Debrecen, Not set

Research Site, Szeged, Not set

Research Site, Ahmedabad, Not set

Research Site, Dehradun, Not set

Research Site, Gurugram, Not set

Research Site, Hyderabad, Not set

Research Site, Kolkata, Not set

Research Site, Mumbai, Not set

Research Site, Mysuru, Not set

Research Site, New Delhi, Not set

Research Site, Puducherry, Not set

Research Site, Secunderabad, Not set

Research Site, Afula, Not set

Research Site, Haifa, Not set

Research Site, Jerusalem, Not set

Research Site, Kfar Saba, Not set

Research Site, Ramat Gan, Not set

Research Site, Ancona, Not set

Research Site, Bari, Not set

Research Site, Catania, Not set

Research Site, Milano, Not set

Research Site, Milan, Not set

Research Site, Padova, Not set

Research Site, Palermo, Not set

Research Site, Pavia, Not set

Research Site, Pisa, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Siena, Not set

Research Site, Asahikawa-shi, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chiba-shi, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Iruma-Gun, Not set

Research Site, Kawachinagano-shi, Not set

Research Site, Kawasaki-shi, Not set

Research Site, Nagoya-shi, Not set

Research Site, Okayama-shi, Not set

Research Site, Omura-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Tachikawa-shi, Not set

Research Site, Yotsukaido-shi, Not set

Research Site, Daejeon, Not set

Research Site, Seoul, Not set

Research Site, Ciudad de Mexico, Not set

Research Site, Culiacan, Not set

Research Site, D.F, Not set

Research Site, Guadalajara, Not set

Research Site, Mexico City, Not set

Research Site, Mexico, Not set

Research Site, Amsterdam, Not set

Research Site, Białystok, Not set

Research Site, Kraków, Not set

Research Site, Poznań, Not set

Research Site, Warszawa, Not set

Research Site, Wrocław, Not set

Research Site, Łódź, Not set

Research Site, Caguas, Not set

Research Site, San Juan, Not set

Research Site, Barcelona, Not set

Research Site, Cordoba, Not set

Research Site, L'Hospitalet de Llobregat, Not set

Research Site, La Coruña, Not set

Research Site, Madrid, Not set

Research Site, Sabadell, Not set

Research Site, Valladolid, Not set

Research Site, Stockholm, Not set

Research Site, Uppsala, Not set

Research Site, Kaohsiung, Not set

Research Site, New Taipei, Not set

Research Site, Taichung, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Edinburgh, Not set

Research Site, London, Not set

Research Site, Wolverhampton, Not set

Research Site, Ha Noi, Not set

Research Site, Hanoi City, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh city, Not set

Research Site, Ho Chi Minh, Not set

Research Site, Hochiminh city, Not set

Research Site, Hue, Not set

Conditions: Polymyositis, Dermatomyositis

Learn More ›